Welcome to our dedicated page for SILICON LABORATORIES SEC filings (Ticker: SLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SILICON LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SILICON LABORATORIES's regulatory disclosures and financial reporting.
Silicon Laboratories Inc. reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Texas Instruments Incorporated expired at 11:59 p.m. Eastern Time on May 22, 2026. This expiration satisfies one of the conditions required to close the merger, under which Silicon Labs will become a wholly owned direct subsidiary of Texas Instruments. The closing of the transaction still depends on other customary conditions, including receipt of additional regulatory approvals and satisfaction of requirements in the Merger Agreement.
SILICON LABORATORIES INC. Senior Vice President and CFO Dean Warren Butler reported a routine tax-related share disposition. On the reported date, 6,291 shares of common stock were withheld to cover taxes due upon vesting of a previously reported equity award, rather than sold in the open market. After this withholding, Butler directly holds 43,767 shares of Silicon Labs common stock.
Silicon Laboratories Inc. executive reports routine tax withholding. Sr VP and General Manager Robert J. Conrad had 3,653 shares of common stock withheld on 2026-05-15 to cover taxes upon vesting of a previously reported equity award at an indicated price of $216.59 per share. After this non-market tax-withholding disposition, he directly holds 30,396 shares of Silicon Laboratories common stock.
SILICON LABORATORIES INC. President & CEO Robert Matthew Johnson reported an open-market sale of 8,024 shares of common stock at $216.83 per share on May 18, 2026, leaving him with 80,519 directly held shares.
On May 15, 2026, 10,363 shares were disposed of at $216.59 per share to cover taxes upon the vesting of a previously reported equity award, a tax-withholding event rather than a market sale.
SILICON LABORATORIES INC. Chief Accounting Officer Mark D. Mauldin reported a routine tax-related share disposition. On May 15, 2026, 858 shares of common stock were withheld at $216.59 per share to cover taxes upon vesting of a previously reported equity award. After this withholding, Mauldin directly holds 21,090 shares of common stock. This was a tax-withholding event, not an open-market sale or purchase.
Silicon Laboratories Inc. senior vice president of worldwide sales and marketing Brandon Tolany reported a routine tax-related share disposition. On May 15, 2026, 4,160 shares of common stock were withheld at $216.59 per share to cover taxes upon vesting of a previously reported equity award. Following this withholding, Tolany directly holds 66,935 shares of Silicon Labs common stock. This event reflects compensation-related tax withholding, not an open-market sale.
Silicon Laboratories Inc. reports higher Q1 revenue but remains unprofitable while progressing toward an all-cash sale to Texas Instruments. Revenue for the quarter ended April 4, 2026 rose to $213.5 million from $177.7 million, driven by strong Industrial & Commercial and Home & Life demand. Gross margin improved to 59.5%, and the net loss narrowed to $15.9 million, or $0.48 per share, compared with a $30.5 million loss a year earlier.
Cash, cash equivalents and short-term investments totaled $438.9 million, with positive operating cash flow of $4.9 million and no borrowings on a $400 million revolving credit facility. The company entered into a Merger Agreement under which each share will be converted into the right to receive $231.00 in cash, subject to customary closing conditions, with closing expected in the first half of 2027. Silicon Labs recorded $11.2 million of merger-related costs in the quarter and highlights ongoing macroeconomic and geopolitical risks, as well as regulatory and closing risks related to the proposed transaction.
Silicon Laboratories Inc. reported first-quarter 2026 results with revenue of $213.5 million and non-GAAP diluted earnings per share of $0.53. Revenue grew 20% year-over-year, led by Industrial & Commercial revenue of $128 million, up 33%, and Home & Life revenue of $86 million, up 5%.
On a GAAP basis, the company posted a net loss of $15.9 million, or $0.48 per diluted share, with a GAAP gross margin of 59.5%. Non-GAAP operating income was $18.1 million with a 59.7% non-GAAP gross margin. Silicon Labs ended the quarter with $383.1 million in cash and cash equivalents and has suspended forward-looking guidance due to the pending acquisition by Texas Instruments.
Silicon Laboratories Inc. Chief Accounting Officer Mark D. Mauldin acquired 18 shares of common stock on the issuer’s employee purchase date at a price of $86.46 per share. After this transaction, he directly holds 21,948 common shares.
The shares were acquired through Silicon Laboratories’ 2009 Employee Stock Purchase Plan in a transaction described as exempt under Rule 166-3(c) and Rule 166-3(d), indicating this was a routine, compensation-related purchase rather than an open-market trade.